A U.S. Food and Drug Administration advisory panel has sparked intense controversy after voting Thursday to recommend rolling back restrictions on the buzzy wellness industry peptide BPC-157, a decision that splits public health experts and opens new debate over untested compounded drugs. The recommendation came during a two-day gathering where the committee is evaluating whether seven understudied peptides should be added to the FDA’s approved bulk compounding list, a designation that lets specialized compounding pharmacies produce custom peptide formulations for wider public access.
Peptides, short amino acid chains that form the building blocks of proteins, occur naturally in the human body. But synthetic versions like BPC-157 have exploded in popularity in mainstream wellness circles, promoted by social media influencers and A-list celebrities as a miracle solution for everything from injury recovery to overall bodily optimization, despite a near-total lack of rigorous human clinical trial data to back up those claims.
Critics have already raised alarms over the composition of the advisory panel, noting that current U.S. Health Secretary Robert F. Kennedy Jr.—himself a public proponent of peptide use who says he has taken peptides to treat personal injuries—stacked the committee with appointees holding deep financial and professional ties to the growing peptide industry. The peptides now under review, which also include TB-500 and Semax, were previously restricted from compounding by the administration of former president Joe Biden, largely due to the absence of proven safety and effectiveness data from formal human trials.
Even before the panel’s vote, unregulated access to these peptides remained widespread. Consumers can already purchase the substances online from chemical suppliers marketed as “for lab use only,” and the products are regularly promoted across social media platforms among wellness trend followers, biohackers, and high-profile public figures including Kennedy.
The final vote on BPC-157 ended 8-6 in favor of adding the peptide to the approved compounding list, with one panel member abstaining. The outcome directly contradicts the formal warnings issued by FDA career scientists, who have repeatedly emphasized that BPC-157 lacks sufficient data to confirm it is safe or effective for human use.
Panel members who opposed the recommendation stood by their objections during the open meeting. Elizabeth Rebello, a practicing pharmacist and anesthesiologist, told the committee she voted against the move “because of the lack of efficacy data” and ongoing “safety concerns.” Fellow no-voter Brian Lee added: “I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes.”
The majority of voting panelists justified their support for loosening restrictions by citing arguments of “medical freedom” and the “greater good” of expanding patient access to experimental treatments.
The vote followed hours of testimony from stakeholders on both sides of the debate, including stark warnings from FDA career scientists against expanding access to untested BPC-157. Peter Lurie, president of the nonpartisan Center for Science in the Public Interest and a former FDA official, urged the panel to maintain existing restrictions, arguing that the recommendation “is inconsistent with the FDA’s own standards for pharmacy compounding, poses dangers to consumers, and removes incentives for developing new pharmaceutical products through the standard drug approval process.” Lurie went on to frame the unregulated peptide industry as a landscape rife with “pseudoscience and grift.”
On the opposing side, telehealth firms including Hims & Hers argued in favor of easing restrictions, warning that keeping tight limits on compounded peptides will only push consumers to purchase unregulated products from unvetted gray market sellers, increasing rather than reducing safety risks.
It is important to note that not all synthetic peptides carry the same level of risk: common treatments such as insulin and GLP-1 are well-studied, with well-documented risk and benefit profiles that have been confirmed through years of clinical research. By contrast, the injectable synthetic peptides promoted by wellness influencers and biohackers have never completed the large-scale, controlled clinical trials the FDA requires to formally confirm safety and effectiveness for consumer use.
The advisory panel will continue its review of the six remaining peptides over the second day of the scheduled meeting. While the committee’s final recommendations are not legally binding for the FDA, the agency has a long-standing history of giving substantial deference to advisory panel guidance when setting regulatory policy.